कृपया अन्य खोज का प्रयास करें
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Michael Baker | - | 2020 | CEO, MD & Director |
Thomas Duthy | - | 2023 | Non-Executive Chair |
Reuben Benjamin | - | 2021 | Member of Scientific Advisory Board |
Elizabeth Stoner | 73 | 2021 | Non-Executive Director |
Anastasios Karadimitris | - | - | Chairman of Scientific Advisory Board |
Gary Jonathan Phillips | 62 | 2022 | Independent Non-Executive Director |
John Maher | - | 2021 | Member of Scientific Advisory Board |
Debora Barton | 47 | 2021 | Independent Non-Executive Director |
Gianpietro Dotti | - | 2024 | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है